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Abstract
Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heteroge-
neous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are indi-
vidualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in
patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent
or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in
SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy
remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers,
have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and
discusses our current understandings in treating children with idiopathic SRNS.
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Introduction
Nephrotic syndrome is the most common glomerular disease
in childhood. The prevalence is 12–16 per 100,000 children
aged under 16 [1]. The reported annual incidence in children
varies between 1.2 and 3.5 per 100,000 per year in Western
Europe [2–4], 4.7 per 100,000 per year worldwide [5] and up
to 6.5 per 100,000 per year in Japan [6]. Although more than
85% of children with nephrotic syndrome respond to cortico-
steroids, approximately 10–15% remain unresponsive or later
become steroid-resistant [7–11]. Steroid-resistant nephrotic
syndrome (SRNS) has been associated with unfavourable re-
nal prognosis, with 36–50% of patients progressing to end-
stage kidney disease within 10 years [12–14].
Standardized management of SRNS has been hampered by
the paucity of high-quality trial evidence. SRNS is rare, and as
such treatment options are based on anecdotes, case reports
mainly illustrating individual centre practice and studies with
relatively small numbers of patients. Protocols are therefore
generally individualized using a broad framework. In addi-
tion, there are few clinical studies with a sufficient power in
children with SRNS.
Recent perspectives on the stratification
of nephrotic syndrome
For many years, idiopathic nephrotic syndrome has been clas-
sified based on the patient’s response to steroids: as steroid-
sensitive or steroid-resistant. SRNS, most commonly focal
segmental glomerulosclerosis (FSGS) in histology, has long
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been thought as an immune-mediated disease, either with or
without circulating factors. However, recent techniques have
enabled the discovery of a multitude of genetic mutations that
cause nephrotic syndrome. Because this genetic disease group
is not immune-mediated, it is theoretically unresponsive to
steroids or other immunosuppressants and thus is classified
as SRNS. Monogenic, non-immune-mediated causes report-
edly account for up to one third of SRNS cases overall, and to
date more than 60 genes related to SRNS have been described
[15, 16]. Therefore, SRNS is now a rather heterogeneous con-
stellation of distinct aetiologies. As to this, a recent compre-
hensive review by Saleem [15] has proposed a novel molecu-
lar stratification of SRNS based on disease mechanisms as
monogenic, immune-mediated with circulating factors and
immune-mediated without circulating factors.
This review attempts to appreciate the newly proposed
stratification by summarizing the treatment of monogenic
SRNS in a separate section; however such efforts are limited
because most publications have not (or could not at the time)
stratified patients by their genetic bases. Nevertheless, this
review attempts to summarize current understandings and
controversies in therapies available for children with idiopath-
ic (primary) SRNS.
Intensified immunosuppression and adjuvant
agents for SRNS
Intravenous methylprednisolone pulse
The mechanism of action of steroid therapy in inducing remis-
sion is complex. Its main actions are immune modulation by
binding to specific cytoplasmic receptors, modifying tran-
scription and protein synthesis and thereby suppressing in-
flammatory reactions and humoral immune response [17,
18]. The rationale for administration of intravenous methyl-
prednisolone pulse despite initial steroid unresponsiveness is
based on the results from observational studies which reported
remission in steroid- and/or cyclosporine-resistant nephrotic
syndrome. Previous studies reported remission induced in
SRNS using methylprednisolone pulses with concomitant im-
munosuppressants [19–21] and by methylprednisolone alone
[22, 23]. Specifically, Mori et al. reported remission after
methylprednisolone pulse therapy in 78% (7/9) of patients
who were resistant to steroids and cyclophosphamide (CPM)
and/or cyclosporine A (CSA) [23]. The studies showed that
prolonged methylprednisolone pulses with alternate-day oral
steroidsmay be efficacious, evenwhen patients are considered
to have steroid- and multidrug-resistant nephrotic syndrome.
Mechanisms leading to such a late remission following steroid
pulses despite initial resistance need to be elucidated [12].
However, several studies argue against the use of prolonged
high-dose steroids in SRNS [9, 24, 25], given the adverse
effects of long-term steroid use. In addition, in the PodoNet
registry, a large web-based clinical database in Europe for id-
iopathic SRNS including congenital nephrotic syndrome and
high-dose steroids (including pulses) used as first-line therapy
were not efficacious in ~ 85% [9]. Still, if there was a partial
remission seen with conventional oral prednisolone therapy, it
appears to be worth trying intravenous methylprednisolone
pulses as combination therapy.
Calcineurin inhibitors
There are twomechanisms of the antiproteinuric effect exerted
by calcineurin inhibitors (CNI) discussed (1) through inhibi-
tion of T-cell signalling in lymphocytes and (2) direct non-
immune effects on the podocyte actin cytoskeleton [7, 26].
The latter part of the mechanism explains the partial efficacy
of CNIs in non-immune-mediated, monogenic SRNS, report-
ed in the literature [27]. Complete or partial remission rates in
SRNS with the use of CNIs have been in the range of 30–80%
in observational studies [11] and randomized controlled trials
(RCTs) [28, 29].
A multicentre RCT [29] showed that CNIs significantly
increased the proportion of children with SRNS obtaining
remission, compared with intravenous CPM. This finding
was supported by a systematic review of RCTs by Hodson
et al., which showed that CSA was effective irrespective of
renal pathology compared with placebo and intravenous CPM
[30].
Combination of steroids and CNIs has been proven effica-
cious for treating SRNS in systematic reviews [28, 30] and is
currently recommended by the Kidney Disease Improving
Global Outcomes (KDIGO) guideline [12]. The guideline rec-
ommends continuation of CNI in SRNS for a minimum of
12 months [31]. This statement was supported by a study
highlighting the benefits of continued treatment with tacroli-
mus (TAC) for 18 months [32]. There is, however, no inter-
national consensus on duration of treatment or optimal target
trough levels.
While other CNIs like voclosporin are currently being test-
ed in clinical trials, CSA and TAC are the two major agents
which are commonly used in the treatment of nephrotic syn-
drome. TAC and CSA are generally accepted to have similar
therapeutic effects [7], showing similarly superior efficacy
over CPM [29] and no significant difference in the numbers
of SRNS patients achieving remission [30, 33]. Prasad et al.
studied 45 children with SRNS who were resistant to CPM, in
which they treated the patients with either CSA or TAC and
compared treatment outcome at 6 months [33]. They showed
that CNIs were effective in CPM-resistant nephrotic syndrome
and reported comparable results of TAC and CSA in inducing
remission in 70% and 82% of patients, respectively (P = 0.3)
[33]. However, Choudhry et al. showed that significantly fewer
children relapsed in the TAC-treated group compared to the
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CSA-treated group [34], suggesting superior efficacy of TAC
over CSA.
Concerns exist regarding chronic nephrotoxicity with the
use of long-term CNI. Continuation of CNIs for more than 2
to 5 years has been shown to be associated with renal toxicity
[32, 35, 36]. In patients with steroid-dependent nephrotic syn-
drome (SDNS), chronic histologic lesions due to CNI use
were reported in as high as 35–75% of patients on renal biopsy
[37–40]. For SRNS, Fujinaga et al. performed protocol biop-
sies in six SRNS children who used CSA for more than
2 years, and 87% (5/6) had nephrotoxic histologic changes
[41]. These figures, however, are not directly comparable be-
cause the time points to perform a renal biopsy are not uniform
between the studies. Still, it appears that incidence of nephro-
toxicity is higher in patients with SRNS compared to those
with SDNS [42].
With regard to nephrotoxicity, TAC appears to have a lower
potential risk [43], and a multicentre study on SRNS patients
has suggested a better preserved, long-term renal function in
the TAC-treated group compared to CSA treatment [13],
showing less arteriolopathy and interstitial fibrosis on renal
biopsy [14]. In the study by Prasad et al. [33], 45 children
with SRNS treated with either CSA or TAC were compared
for renal survival at 1, 2, 3, 4 and 5 years. The results demon-
strated that TAC had significantly superior outcomes in terms
of long-term renal function (P = 0.02) [33]. Moreover, a study
by Delbet et al. in 21 paediatric SDNS patients on CNI for
more than 12months found relatively infrequent (only 1 out of
21) renal histology of CNI nephrotoxicity, which the authors
explained by a greater use of TAC over CSA [43].
Furthermore, in an RCT with 124 renal transplant recipients,
conversion from CSA to TAC resulted in stabilized serum
creatinine levels (whereas the CSA-continuation group had a
significantly greater rise in serum creatinine) and resulted in a
sustained reduction of blood pressure, improvement in serum
lipid profile and quality of life [44]. In contrast, another study
on renal transplant recipients reported comparable incidence
of arteriolopathy between TAC and CSA [45].
Nevertheless, most centres have changed their prescription
pattern towards TAC, as it appears to exhibit better efficacy
and less systemic side effects, particularly nephrotoxicity. In
addition, compared to CSA, TAC has fewer cosmetic side
effects, such as gingival hypertrophy and hirsutism [34].
RCTs comparing both agents with a long-term follow-up are
necessary to specifically address these points, and generaliz-
able recommendations may be extrapolated thereafter.
Cyclophosphamide
CPM is an alkylating agent lowering the immune response and
thereby used in several autoimmune diseases. It has been prov-
en effective in maintaining remission and reducing relapses in
steroid-sensitive nephrotic syndrome (SSNS). For SRNS,
however, a body of literature suggested its limited efficacy in
inducing sustained remission [8, 9, 46–50], and there are cur-
rently no RCTs advocating the use of CPM in SRNS. Instead,
CNIs are accepted for superior efficacy to CPM in the man-
agement of SRNS. A comparative study on the treatment ef-
fects of CPM and CSA was performed in 127 children with
SRNS. At 5 years of follow-up, a higher response rate has been
observed in 65 children receiving CSA for 2 years compared to
62 patients assigned to CPM treatment for 3 to 6 months
(70.8% vs. 51.6%, P = 0.027), and a relapse-free survival also
favoured CSA over CPM (38.3 vs. 32.5 months, p < 0.001)
[51]. Similarly, superior effects were seen with TAC, showing
significantly shorter mean time to remission compared with
CPM [29]. These findings were supported by a systematic
review showing that CNIs significantly increased the number
of patients achieving remission compared with CPM [30]. In
this systematic review, CPM plus steroids had no benefit com-
pared to steroid monotherapy [30]. Moreover, with its substan-
tial side effect, spectrum needs to be considered, such as go-
nadal dysfunction, myelosuppression and increased long-term
risk of malignancy [52]. Thus, the use of CPM for SRNS is
rather discouraged and officially not recommended by the
KDIGO guidelines (Table 1) [12].
Mycophenolate mofetil
Mycophenolate mofetil (MMF) modulates the immune re-
sponse by inhibiting inosine monophosphate dehydrogenase,
a key enzyme involved in purine biosynthesis [26], and there-
by inducing selective inhibition of DNA replication in Tand B
lymphocytes [7].
MMF has been effectively used as a remission-maintaining
and steroid-sparing agent for children with SSNS, including
frequently-relapsing nephrotic syndrome (FRNS) or SDNS
[8, 80]. For SRNS, several observational studies using MMF
have demonstrated complete remission in 23–62%, partial re-
mission in 25–37% and no response in 8–40% of patients,
although the results were largely impacted by a high likeli-
hood of publication bias due to small numbers of patients [12,
56, 81, 82]. MMF has also been suggested to be effective in
children with SRNS under the age of 2 years [56].
Contrastingly, in a large longitudinal study from the
PodoNet registry, MMF monotherapy during the first year of
disease onset in 612 SRNS patients led to no remission in
most (83.3%) cases [11]. However, it should be noted that
the registry contains both immune-mediated and monogenic
SRNS. In addition, an RCT including children and adults
compared dexamethasone (high cumulative exposure) plus
MMF (DEX/MMF) to CSA monotherapy [55], showing no
benefit of the former over the latter. In this study, sustained
response was reported in 33.3% of subjects receiving DEX/
MMF and 45.9% in those receiving CSA [55]. A systematic
review also found no statistically significant difference in the
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number of remissions between a combination of MMF/
steroids to CSA or TAC monotherapy [30]. Moreover, an
open-label RCT demonstrated that MMF was inferior to
TAC in sustaining remission in 60 children with SRNS [32].
In this study, in patients who had previously achieved com-
plete or partial remission using TAC, a switch from TAC to
MMF at 6 months failed to maintain remission, yielding a
twofold increased incidence of relapses and leading to higher
prednisolone exposure [32].
Still, MMF is sometimes preferred for its relative safety
with respect to nephrotoxicity. In the National Institutes of
Health (NIH)-funded FSGS study, the authors reported a sig-
nificantly lower median glomerular filtration rate (GFR) at
6 months after treatment in FSGS patients receiving CSA
compared with those receiving DEX/MMF [55], which was
further supported by an RCT in SSNS [83]. However, an RCT
in children with SRNS showed no difference in GFR between
MMF- and TAC-treated patients [32].
In general, the efficacy of MMF in patients with SRNS
appears less satisfactory than in those with SSNS [32] and
seems not superior to CNI monotherapy in SRNS.
Nevertheless, MMF can be effective as an additive agent in
maintaining CNI-induced [84–86] and rituximab (RTX)-in-
duced remission [87] in SRNS patients, although premature
switching to MMF is not recommended [32]. MMF may also
be an alternative in patients who are resistant to CNI, which
will be discussed below.
Levamisole
Levamisole is an immune-modulating anthelminthic that has
been considered the least toxic and least expensive steroid-
Table 1 Efficacy of treatment options used in the management of cases with SRNS
Drug Dose
(may differ by centres)
Efficacy Recommendationa
RAS inhibitors – In 40–50% lowered PU [53, 54]
CR in 27%, PR in 21% [9]
Yes [7, 8, 53, 54]
Steroid pulse 30 mg/kg (max.1 g) QOD
Mendoza protocol for 82 weeks
No effect in ~ 85% [9]
CR or PR in 33–53% [12, 48, 55]
CR in 7%, PR in 11%, no effect in 83% [11]
No [9]
Cyclophosphamide IV 500 mg/m2
PO 2 mg/kg/d
(max. cumulative dose 168 mg/kg)
No effect [12]




PO 1200 mg/m2/d #2 CR 23–62%, PR 25–37% [12, 52, 56]
CR in 8%, PR in 8%, no effect in 83% [11]
No for monotherapy [11, 30, 55]
Yes for triple therapy [57]
Calcineurin inhibitors Cyclosporine 4–6 mg/kg/day #2
(trough 150–300 mg/ml)
Tacrolimus 0.1–0.2 mg/kg/day #2
(trough 5–15 μg/ml)
CR or PR in 70% [7]
CR or PR in 50–70% [7]
CR or PR in 30–80% [28]
CR in 30%, PR in 19% [11]
Yes [7, 28, 30]
Rituximab IV 375 mg/m2 weekly or biweekly CR in 44%, PR in 15% [9]









CR or PR in 5/5 pt. [67]
CR or PR in 2/4 pt. [68]
CR or PR in 4/4 pt. [64]
Little evidence
Abatacept/Belatacept Abatacept 10 mg/kg once or twice daily CR or PR in 5 pt. [69]




SC 24 mg/m2 (max.40 mg) biweekly Phase I trial: PR in 40% [71]
Phase II trial: no response [72]
No (Phase II) [53]
Fresolimumab
(mAb TGF-ß)
1 mg/kg or 4 mg/kg Phase I trial: CR or PR in 18% [53]
Phase II trial: no response [73]
No (Phase II) [73]
Galactose PO 0.2 g/kg (max.15 g) twice daily Phase II trial: CR or PR in 40% [72]
PR in 29% [72, 74, 75]
No effect in PU [76]
Yes (Phase II) [72]
ACTH analogues Gel 80 U/1.73 m2 twice weekly
IM 1 mg weekly × 12 months
PR in 29% [77]
CR in 33% (6/18) and PR in 22% (4/18) [78]
Little evidence
Sparsentan 200, 400, 800 mg/d More efficacious than irbesartan after 8 weeks
[79]
Little evidence
CR complete remission; PR partial remission; mAb monoclonal antibody; IV intravenous; PO per oral; SC subcutaneous; QOD every other day
a Recommended by one of the followings: systematic reviews, meta-analysis, official guidelines, reviews, phase I or II clinical trials
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sparing agent for preventing relapses in SSNS [88].
Levamisole is a synthetic imidazole derivative which, instead
of suppressing immunity, enhances humoral immune response
and macrophage activation [89] and induces type 1 (Th1) and
type 2 (Th2) T-cell responses through enhancing IL-18 activ-
ity [90]. In a human podocyte model, levamisole was shown
to induce expression of glucocorticoid receptor, and it has
been suggested that glucocorticoid signalling is a critical tar-
get of levamisole action [91].
Levamisole was shown to be effective in reducing the fre-
quency of relapses in adult patients with SSNS [91], which
was supported by a systematic review of RCTs [92]. In chil-
dren with SSNS, a recent open-label RCT showed that levam-
isole had comparable and satisfactory efficacy compared to
MMF in maintaining sustained remission [93].
With respect to SRNS, however, there is a paucity of data
supporting the use of levamisole. In their experience with
levamisole treatment in children with SSNS and SRNS,
Tenbrock et al. concluded that levamisole had a clinical ben-
efit in SSNS but not in SRNS [94]. Few studies thereafter have
been performed in SRNS. In short, the efficacy of levamisole
in SRNS so far appears limited.
mTOR inhibitors
Mammalian target of rapamycin (mTOR) signalling is in-
volved in a variety of kidney diseases. mTOR inhibitors are
assumed to work through control of autophagy [95]. They
block T-cell proliferation and bind to the same immunomod-
ulators as TAC, without affecting the activity of calcineurin
[96]. Low-dose rapamycin, an inhibitor of the mTOR, has
been reported to diminish disease progression in an experi-
mental model of FSGS [97]. Rapamycin has been successfully
used in a case series including three patients with FSGS [98]
and in ten children with SRNS [96]. Moreover, in a prospec-
tive, open-label trial of sirolimus to treat steroid-resistant
FSGS, complete or partial remission was reported in 47% of
the treated patients [99]. However, a phase II open-label clin-
ical trial study on sirolimus had to be prematurely
discontinued due to renal functional deterioration after admin-
istration [100]. In addition, mTOR inhibitors at high dose may
rather cause aggravation of proteinuria in FSGS [100]. Given
their potential detrimental renal effects, the use of mTOR in-
hibitors in cases of SRNS is discouraged.
Therapy for CNI-dependent or CNI-resistant SRNS
A subset of SRNS patients is CNI-dependent, who respond to
CNI treatment but relapse once therapy is tapered or
discontinued, and another proportion is resistant to CNI.
Since prolonged use of high-dose CNI can result in undesir-
able side effects (i.e. nephrotoxicity), alternative or additive
drugs have been sought.
El-Reshaid et al. treated 21 CNI-resistant SRNS patients
with CNI in combination withMMF and monthly intravenous
CPM for a total of 3 pulses and induced complete remission in
71% (15/21) [101]. Former triple therapy approaches com-
prised CNI plus prednisolone and a third agent, such as
MMF [102, 103] or mizoribine [104] (Table 2). Of these,
MMFmay be an effective third agent, supported by additional
reports which show that remission was achieved in 20 to 50%
of patients refractory to treatment with CNIs and corticoste-
roids [32, 105, 106]. Some retrospective case series have also
showed that MMF, as a maintenance agent, enabled CNI- and
steroid-free remission in some patients with CNI dependence
and/or toxicity [32, 107, 108]. Still, as discussed in the previ-
ous section of this review, MMF as a monotherapy or in dual
combination with prednisolone was not superior to CNIs in
terms of inducing remission in SRNS [30, 32]. Wu et al. then
performed a prospective RCT in 18 children with steroid- and
TAC-resistant or TAC-dependent nephrotic syndrome [57].
They reported that triple-combination therapy with predniso-
lone, TAC and one out of MMF, CPM or leflunomide was
effective for short-term response and remission at 1 year, with
comparable efficacy between the three agents and without
significant side effects [57]. However, prolonged intensive
immunosuppression with a combined regimen may predis-
pose patients to serious infectious complications and potential
malignancy risk in the long term, and this should be closely
monitored. Therefore, novel agents that could be used for a
shorter period of time as pulse therapy have been sought,
namely, monoclonal antibodies.
Anti-CD20 monoclonal antibodies
Rituximab and novel CD20-blocking agents
Multidrug-resistant patients who are unresponsive to above
listed agents – steroids, CNI and MMF – pose a great chal-
lenge for nephrologists. Monoclonal antibodies have been in-
vestigated as salvage therapy for these patients.
Rituximab (RTX) is a chimeric anti-CD20 monoclonal an-
tibody which has been used as an alternative steroid-sparing
agent for SSNS patients since the early 2000s and is generally
well tolerated. Its main action on immune regulation is
through targeting the cell surface antigen CD20 on B lympho-
cytes and inducing B-cell depletion [26]. In addition, a non-
immune-related mechanism of action has been proposed.
RTX reportedly could affect podocyte function through stabi-
lization of sphingomyelin phosphodiesterase acid-like 3b
(SMPDL-3b), preventing podocyte actin remodelling [109].
While RTX has been successfully used in patients with
FRNS or SDNS in recent years [110], a comparative study
by Topaloglu et al. explored the effects of RTX in children
with SSNS (n = 21) and SRNS (n = 20) and concluded that
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RTX had more positive therapeutic effects in patients with
SSNS than in those with SRNS [111].
Although controversial results exist related to its efficacy in
SRNS, it has been generally successful in children with SRNS
[60, 112]. Reportedly, approximately 50% of patients with
refractory SRNS respond to RTX [61], showing complete
remission in 44% and partial remission in 15% [9] of cases.
Studies with more favourable outcomes report response rates
of 63% [113], 67% [87] and 80% [62]. However, contrasting-
ly, non-response rates of 81% [63] and 71% [112] were found
by other publications. A recent systematic review of RCTs
reported remission with RTX in 46% of SRNS (63% with
MCD and 39% with FSGS) and sustained remission among
responders in up to ~ 94% [58]. However, an open-label RCT
in patients with refractory SRNS by Magnasco et al. demon-
strated no additional benefit of RTX over CNI [63].
There is a recent study by Fujinaga et al. reporting 100%
complete remission in children with SRNS receiving RTX
[41]. This study is noteworthy because the authors empha-
sized the significance of timing of RTX initiation in SRNS
patients. In the study, the authors investigated long-term out-
comes after early application of RTX in six Japanese children
who were unresponsive to a combination of CSA and intra-
venous methylprednisolone pulses [41]. The patients had
RTX treatment within 6 months of disease onset (median
11 weeks), followed by retrial of high-dose intravenous meth-
ylprednisolone (2 mg/kg/d) and oral prednisolone and then
switched to maintenance oral immunosuppressants (MMF or
CSA). Using this protocol, all six patients achieved complete
remission at a median of 158 days and maintained remission
(although there were relapses) for a follow-up period of
5.1 years, without developing renal insufficiency [41]. In the
previous open-label RCT in patients with refractory SRNS by
Magnasco et al., two standard doses of RTX were not able to
induce remission within 3 months after administration [63]. It
is important to note that in the study by Fujinaga, most pa-
tients (4/6, 67%) achieved remission after 3 months of RTX
administration with repeated doses (one patient required eight
doses of RTX until complete remission was achieved) [41].
The authors suggested that in case of unresponsiveness, re-
peated administration over a longer period of time can be
effective in SRNS. Evidence supports the concept that serum
RTX levels may decrease more rapidly in SRNS due to per-
sistent urinary losses [114, 115]. In that sense, it appears to
require more doses in SRNS patients who have uncontrolled
proteinuria [41, 116]. Moreover, the time from diagnosis of
SRNS to the first RTX infusion was 2.5 years in the RCT by
Magnasco et al. [63] and 2.2 years in the study by Topaloglu
et al. [111], while it was 11 months in Fujinaga et al.’s study
[41]. It may be speculated that a long-lasting nephrotic state
leads to irreversible histologic changes, such as fibrosis and
glomerulosclerosis [41], which results in imperfect response
to RTX treatment. This view was supported by an observa-
tional study by Kamei et al., in which seven out of ten (70%)
SRNS patients responded after repeated doses of RTX follow-
ed by intravenous methylprednisolone pulses and an addition-
al oral immunosuppressant [62]. In this study, the seven pa-
tients who received RTX within 6 months of disease onset
achieved complete remission, while two patients who had a
longer duration of disease (61 and 121 months, respectively)
progressed to end-stage kidney disease [41, 62].
Although rituximab is generally safe and well tolerated in
most children, there are potentially serious adverse events that
require caution: hypogammaglobulinemia, late-onset neutro-
penia, hepatitis B reactivation, serious infusion-related ad-
verse events and infections, the latter with potentially fatal
outcome with reports of Pneumocystis jirovecii pneumonia
and progressive multifocal leukoencephalopathy [8, 58, 59,
61, 62, 117, 118]. In the study by Fujinaga et al., although
all six patients achieved complete remission, four of the six
had hypogammaglobulinemia requiring intravenous immuno-
globulins (IVIG), and one of them developed persistent
hypogammaglobulinemia demanding regular IVIG treatment
(despite re-emergence of B-cells in the blood) [41]. Such
Table 2 Combination treatment for CNI-resistant or CNI-dependent SRNS





Pd + TAC +MMF/CPM/leflunomide
(3rd agents had equal efficacy)
Short term response 14/18 (78%)




21 CNI-resistant MCD/FSGS CNI +MMF + IV CPM (for 3 months) Complete remission 15/21 (71%) 6.5 yr
Ballarin,
2007 [98]





2 CSA-resistant children Pd + TAC +mizoribine 2/2 complete remission 8 mo and 17 mo
Kim,
2014 [99]
8 refractory SRNS Pd + TAC +MMF 75% response N/A
CR complete remission;PR partial remission; TAC tacrolimus; Pd prednisolone,MMFmycophenolate mofetil;CPM cyclophosphamide; F-U follow-up;
CNI calcineurin inhibitor; MGN membranous glomerulonephropathy; MCD minimal change disease; FSGS focal segmental glomerulosclerosis; yr
years; mo months; N/A not available
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hematologic adverse effects are reported more often and more
severely in younger children. In previous studies with SRNS
[41] as well as with SDNS [119], those patients who devel-
oped severe neutropenia and hypogammaglobulinemia were
aged under 10 years. In addition, in a Japanese multicentre
study involving 114 children, the median age was significant-
ly younger in patients with more severe hematologic adverse
effects (6.4 vs. 11.5 years) [120]. On the other hand, Bonanni
et al. reported only 2 cases of severe neutropenia out of 100
Caucasian children with multidrug-resistant nephrotic syn-
drome who received RTX [121]. This discrepancy may be
explained by the older age of patients in Bonanni’s group
(median 9.2 years). Although the mechanisms leading to more
complications in younger children are not well understood,
younger age appears to be a particular risk factor for these
adverse events.
To summarize, although RTX treatment in SRNS may not
be as effective as in SSNS, early repeated administration with
higher cumulative doses can be efficacious in the management
SRNS. Early administration within 6 months of disease onset
and a trial of multiple doses followed by methylprednisolone
pulses with high-dose prednisolone showed favourable renal
outcome. Adverse hematologic effects occur more frequently
in children aged under 10.
Ofatumumab
Ofatumumab, a novel humanized anti-CD20 monoclonal an-
tibody, is an alternative to RTX in patients with anti-RTX
antibodies or RTX hypersensitivity. It has also been used in
patients with resistance to RTX [64, 67, 68] including cases
with post-transplantation RTX-resistant SRNS [64, 122].
Ofatumumab successfully achieved remission in paediatric
SRNS with severe adverse reactions to RTX [65] and anti-
RTX antibodies [66]. Efficacy of ofatumumab so far is excep-
tionally positive; its first use reported complete or partial re-
mission in five out of five children with SRNS [67] and in a
more recent study in four out of four children with SRNS who
completed ofatumumab treatment [64]. In the latter study, two
patients experienced hypersensitivity to ofatumumab and re-
ceived desensitization [64]. In a study with lower doses of
ofatumumab, two out of four patients who were resistant to
a combination or steroids, CNIs and MMF, achieved remis-
sion [68].
The side effects, however, were more prevalent with
ofatumumab than RTX in the study by Bonanni et al. [121].
They investigated treatment outcomes in steroid- and
multidrug-dependent nephrotic syndrome using RTX in 137
and ofatumumab in 37 patients. While treatment efficacy was
comparable, infusion reactions, such as skin rash, fever, dys-
pnoea and late adverse effects, were more frequent in the
ofatumumab treatment group [121]. In this study, immediate
infusion reactions were effectively controlled by pretreatment
including steroids, antihistamines and paracetamol, and
salbutamol was critical for preventing respiratory
complications.
In short, ofatumumab is an emerging substitute for RTX-
resistant and RTX-hypersensitive patients with multidrug-
resistant SRNS, although adverse effects and infusion reac-
tions are more common than following RTX administration.
Addition of a beta-mimetic agent in the pretreatment protocol
was helpful in controlling respiratory reaction.
Other monoclonal antibodies
There are a handful of novel monoclonal antibodies which
have been used as potentially effective measures in nephrotic
syndrome. Most of these, however, have been ineffective in
SRNS, and only a few studies exist on paediatric patients.
Abatacept/Belatacept
Abatacept, a cytotoxic T-lymphocyte-associated protein 4
(CTLA-4) immunoglobulin (Ig), blocks the CD28:CD80/
CD86 co-stimulatory pathway and has recently been intro-
duced as a treatment option for FSGS. A study by Yu et al.
showed that B7–1 (CD80) overexpression was induced in
podocytes in primary and recurrent FSGS and reported the
efficacy of abatacept in four post-transplantation patients
(two adults and two children) with recurrent FSGS refractory
to immunosuppression including rituximab, and one adult pa-
tient with FSGS in the native kidney [69]. Controversies re-
main, since B7–1 (CD80) expression on podocytes has not
been reproducible by different research groups [123, 124]
and further research has showed no efficacy of abatacept in
the management of FSGS/SRNS [70, 125]. Further prospec-
tive studies are on their way to prove or disprove the efficacy
of abatacept in SRNS. The effects of belatacept, an agent with
a higher potential to block B7–2 (CD86), also need to be
further addressed.
Adalimumab
Adalimumab is a monoclonal antibody blocking TNF-α [26].
In the FONT phase 1 trial of adalimumab, four out of ten
patients (mean age, 16.8 ± 9.0 years) with primary FSGS
showed a > 50% reduction in proteinuria, achieving partial
remission during a 16-week treatment course [71]. To further
test the hypothesis of adalimumab efficacy in FSGS, the
FONT study group performed a phase II trial including 21
patients (14 children and 7 adults) with primary FSGS [72].
In the phase II trial, however, none of the subjects assigned to
adalimumab achieved a 50% reduction in proteinuria [72].
These findings suggest that adalimumab may not be effective
in the management of FSGS/SRNS.
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Fresolimumab
Fresolimumab is a monoclonal antibody targeting
transforming growth factor-β (TGF-β). Sustained overpro-
duction of TGF-β has been implicated in the pathogenesis
of fibrosis, including human fibrotic kidney diseases and
FSGS [73]. In a phase I clinical trial, complete or partial re-
mission was achieved in 3 out of 16 adults (mean age, 37 ±
12 years) with primary FSGS who were previously unrespon-
sive to CNIs or high-dose steroids, showing a response rate of
18% [53].
In the subsequent phase II trial with fresolimumab for
112 days, however, none of the 36 patients showed a >
50% decline in proteinuria compared to baseline [73]. The
study was prematurely terminated due to futility, since a total
recruitment of 88 patients was planned [73]. Three patients
had some degree of decline in proteinuria but not meeting
the criteria for remission, and fresolimumab was generally
well tolerated [73]. Although the studies may have been
underpowered, fresolimumab is no alternative in treating
SRNS.
Non-immunologic therapies
Renin angiotensin aldosterone system (RAS)
inhibition
Treatment with drugs that inhibit the renin-angiotensin axis
has been recommended for children with SRNS by most of
the previous reviews [7, 8, 26]. The response rate of RAS
inhibition to lower proteinuria is reportedly around 40–50%
in children with SRNS [9, 54, 56]. Furthermore, an RCT in
25 children with SRNS compared the efficacy of enalapril
starting at low dose vs. starting at high dose [54]. The pa-
tients received concomitant steroids but no other immuno-
suppressants. In this study, the high-dose enalapril group
showed significantly higher rates of proteinuria reduction
(33% vs. 52%). Another RCT involving 45 children with
SRNS demonstrated that fosinopril in combination with
prednisolone significantly reduced proteinuria compared to
prednisolone monotherapy [126]. In addition, there was a
case report showing that RAS inhibition can be powerful in
infantile SRNS as well, in which the authors reported com-
plete remission by using RAS inhibition and supportive care
in a 9-month-old patient with FSGS unresponsive to immu-
nosuppression [127]. The patient was screened negative for
NPHS1, NPHS2 and PLCE1 and was not tested for other
genes at that time.
In short, angiotensin-converting enzyme inhibitors or an-
giotensin II receptor blockers are favourable for children with
SRNS and are recommended by current guidelines [12, 31].
Sparsentan
Endothelin type A (ETA) receptor antagonists have emerged
as promising therapies that may enhance RAS inhibitory ac-
tion [79, 128]. Sparsentan is a dual endothelin type A (ETA)
and angiotensin II type 1 receptor antagonist.
A randomized, double-blind, active-control, dose-
escalation study (DUET), a phase II study, compared the effi-
cacy and safety of sparsentan against irbesartan in 96 patients
(aged 8–75 years) with primary FSGS [79]. The results
showed that sparsentan-treated patients had greater reductions
in proteinuria than the irbesartan-treated group after 8 weeks
of treatment [79]. Adverse events of sparsentan were compa-
rable to irbesartan, showing that sparsentan was generally safe
and well tolerated [79]. Although it requires further clinical
experience, this novel agent seems to be a promising non-
immune modulating option for SRNS. Data focusing on pae-
diatric patients are needed in the future.
Galactose
Galactose might reduce proteinuria by binding to putative
circulating factors and inhibiting their activity [26, 78, 129].
Case reports in children and adults suggest that patients with
FSGS/SRNS may benefit from orally given galactose [74, 75,
129]. A prospective clinical trial using galactose in seven chil-
dren with SRNS demonstrated histological improvement in
kidney biopsies but no effect in reducing proteinuria [76].
Nevertheless, a more recent phase II clinical trial showed that
three out of seven FSGS patients treated with oral galactose
showed at least a 50% reduction in proteinuria at 6 months
after initiation and a sustained effect for 3–12 months after
discontinuation of galactose [72], which raised the possibility
of galactose as an adjuvant agent in treating SRNS (Table 1).
ACTH analogues
The exact mechanism of adrenocorticotropic hormone
(ACTH) in reducing proteinuria is not well elucidated. In an
observational study, application of an ACTH analogue in gel
form reduced proteinuria in 11 out of 21 patients with nephrot-
ic syndrome [130]. However, it should be noted that subjects
had a variety of different immunologic kidney diseases, in-
cluding membranous nephropathy, membranoproliferative
nephropathy minimal change disease, immunoglobulin A ne-
phropathy and lupus nephritis [130]. Intramuscular applica-
tion of low-dose ACTH has also been reported to be effective
in a study of 18 adults with nephrotic syndrome, inducing
complete remission in 33% (6/18) and partial remission in
22% (4/18) [131]. In contrast, a recent paediatric RCT – The
ATLANTIS randomized trial for adrenocorticotropic hormone
for childhood nephrotic syndrome – has reported that twice-
weekly administration of ACTH (80 U/1.73m2) was not
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effective in preventing relapses in children with FRNS or
SDNS [132]. With regard to SRNS, one study with 24
FSGS patients reported complete or partial remission in 29%
(7/24) after initiation of ACTH gel treatment, suggesting its
possibility as a treatment option [77]. However, the high ex-
pense of ACTH, the relative lack of evidence [133] and recent
reports on its prescription having been influenced by financial
conflict of interest [134, 135] should prevent hasty recommen-
dations on this drug being made.
Mesenchymal stem cells (MSCs)
Mesenchymal stem cells (MSCs), known for their immuno-
modulatory and anti-inflammatory effects, have been consid-
ered as a potential therapeutic agent for treating immune-
related diseases, including nephrotic syndrome [136, 137].
Currently, a phase I open-label pilot study on safety and effi-
cacy is ongoing (Allogenic AD-MSC Transplantation in
Idiopathic Nephrotic Syndrome (NCT02382874)).
Retinoids
Retinoids are analogues of vitamin A that regulate cellular
differentiation. It has been suggested that retinoids are capable
of restoring podocyte structure in that they reduce proteinuria
in animal models of kidney diseases [138]. A recently com-
pleted phase II trial on the efficacy of retinoids in patients with
FSGS, however, reported no reduction in proteinuria in seven
pa t i en t s who comple t ed i so t r e t i no in t r ea tmen t
(NCT00098020).
Treating monogenic SRNS
Although monogenic SRNS is thought to be inherently non-
immune-based, some cases have been reported to at least par-
tially respond to immunosuppression [27, 139–144].
Moreover, there are familial cases reported as monogenic
SSNS or mixtures of SSNS and SRNS [15, 145–147]. A re-
cent review by Saleem has addressed this issue and proposed
some mechanisms that explain therapeutic efficacy in mono-
genic nephrotic syndrome: (1) the affected genes may play a
role in the immune responses, or (2) mutations in podocytes
may alter their response to immunosuppressants [15]. In ad-
dition, direct effects of corticosteroids [148] and CSA [149]
on podocytes may explain the variable responses to immuno-
suppression in monogenic nephrotic syndrome.
Regarding the efficacy of CSA in genetic SRNS, there have
been further reports from a few cohorts. Buscher et al. studied
immunosuppression outcomes in 91 children with SRNS (in-
cluding congenital nephrotic syndrome) and reported that pa-
tients with Wilms tumour suppressor gene 1 (WT1) mutations
were more responsive to CSA [150]. They further compared
the response to CSA in non-genetic and genetic SRNS in a
larger scale involving 231 patients (131 monogenic SRNS
including 60 congenital nephrotic syndromes) [151].
Therein, they documented response to CSA in 19% of mono-
genic SRNS (3% complete remission and 16% partial remis-
sion). In the PodoNet registry report, there were 74 patients
with documented genetic SRNS, and 14 patients (19%)
showed response to immunosuppression [9].
Specific gene disorders can sometimes benefit from new
therapeutic strategies. Mutations in the genes related to bio-
synthesis of Coenzyme Q 10 (CoQ10, ubiquinone) cause pri-
mary CoQ10 deficiency resulting in various clinical pheno-
types. A portion of these patients present with SRNS, often
with extrarenal manifestations such as sensorineural hearing
loss or neurologic deficit [152–156]. In monogenic SRNS
related to primary CoQ10 deficiency, early initiation of
CoQ10 supplementation has been reported to reduce protein-
uria and delay disease progression [157, 158].
Conclusions
SRNS is a heterogeneous entity, and the treatment effects may
differ by the aetiology. For immune-mediated SRNS, based on
the results from prospective studies and RCTs, the combina-
tion of a CNI and an alternate-day corticosteroid may be the
major strategy. TAC appears to achieve a higher remission rate
compared to CSA and a lower degree of side effects including
nephrotoxicity and gingival hypertrophy. MMF seems not su-
perior to CNI as a monotherapy, but its use in combination
with other measures may be considered in patients with CNI-
resistant or CNI-dependent SRNS. RTX is reported to be less
effective in SRNS, but timely administration with repeated
dosing has shown to induce favourable outcomes. For mono-
genic SRNS, CNIs can be used although not as efficacious as
in immune-based SRNS. Monogenic SRNS associated with
CoQ10 deficiency may benefit from CoQ10 supplementation.
Other novel agents require further validation for efficacy and
safety in managing children with SRNS.
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